Diastolic function in hypertrophic cardiomyopathy: effects of propranolol and verapamil on diastolic stiffness

European Heart Journal
|November 1, 1983
PubMed

Insights

In hypertrophic cardiomyopathy (HCM), propranolol impairs left ventricular (LV) relaxation and diastolic filling, while verapamil improves these functions without altering LV diastolic stiffness.

Area of Science:

  • Cardiology
  • Cardiovascular Physiology
  • Pharmacology

Background:

  • Patients with hypertrophic cardiomyopathy (HCM) often exhibit impaired left ventricular (LV) diastolic filling and relaxation.
  • Understanding the effects of beta-blockers and calcium channel blockers on LV diastolic mechanics is crucial for managing HCM.

Purpose of the Study:

  • To evaluate the impact of propranolol and verapamil on LV diastolic stiffness, relaxation, and filling in patients with HCM.
  • To differentiate the mechanisms by which these drugs affect diastolic function.

Main Methods:

  • Assessed LV diastolic stiffness using pressure-volume data (propranolol group) and stress-strain data (verapamil group) via cineangiography and echocardiography with high-fidelity pressure measurements.
  • Quantified LV relaxation using the time constant of LV pressure decay (T).
  • Measured LV diastolic filling rates (filling rate and midwall lengthening rate).

Main Results:

  • Neither propranolol nor verapamil significantly altered LV chamber or myocardial stiffness.
  • Propranolol significantly increased the time constant of LV pressure decay (impaired relaxation) and decreased mean LV diastolic filling rate.
  • Verapamil significantly decreased the time constant of LV pressure decay (improved relaxation) and increased mean LV midwall lengthening rate.

Conclusions:

  • LV diastolic stiffness remains unchanged in HCM patients treated with propranolol or verapamil.
  • Propranolol exacerbates LV relaxation and diastolic filling impairments in HCM.
  • Verapamil demonstrates a beneficial effect on diastolic mechanics in HCM by improving relaxation and filling, not by altering stiffness.

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.7K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.9K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
952
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753